Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

Fig. 2

Therapeutic effect of selinexor alone or in combination with a BET inhibitor INCB057643 in DLBCL cellular models. a The effect of 72-h selinexor exposure on cell viability of 30 DLBCL cell lines. Waterfall graph showed the specific IC50 value of selinexor for each cell line with either ABC or GCB subtype of DLBCL. b DLBCL cell lines with BCL2 rearrangement (BCL2-R) or HGBCL-DH were more sensitive to selinexor with a lower mean IC50 value compared with other cell lines. c The presence of mutant (Mut) p53 in DLBCL cells significantly reduced the cytotoxicity of selinexor, especially significant in HGBCL-DH cell lines. Selinexor promoted more significant apoptosis in Wt-TP53 HGBCL-DH cells than in Mut-TP53/p53-expressing HGBCL-DH cells. d INCB057643 and selinexor were cooperative in reducing cell viability and inducing apoptosis in HGBCL-DH cells with Wt-TP53 or Mut-TP53/p53+

Back to article page